항암제 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of oncology drugs Market

The global oncology drugs market has witnessed substantial growth due to the rising burden of cancer and continuous advancements in treatment technologies. The market was valued at USD 256.46 billion in 2025 and is projected to reach USD 286.36 billion in 2026, further expanding to USD 697.59 billion by 2034, registering a robust CAGR of 11.77% during 2026-2034.

North America dominated the global market in 2025, accounting for 45.44% of the total share, driven by high healthcare spending, rapid adoption of innovative therapies, and strong regulatory support.

Oncology drugs are prescription medications used to treat various cancers, including solid tumors and hematological malignancies. Increasing adoption of early-stage cancer treatment, supported by advancements in biomarker testing and diagnostics, is significantly driving market growth.

Market Trends

One of the key trends shaping the oncology drugs market is the early use of high-value targeted therapies. The industry is shifting from treating advanced-stage cancers to addressing early-stage conditions, improving survival rates and reducing recurrence risks.

Additionally, the development of subcutaneous drug formulations is gaining traction. These formulations improve patient convenience, reduce hospital time, and enhance treatment efficiency, leading to faster adoption even in competitive drug categories.

Another important trend is the increasing reliance on companion diagnostics, which helps tailor treatments to specific patient profiles, improving clinical outcomes.

Market Drivers

Rising Cancer Burden and Advanced Drug Launches

The increasing prevalence of cancer worldwide is a major growth driver. Factors such as smoking, pollution, lifestyle changes, and aging populations contribute to the rising number of cancer cases.

Simultaneously, the launch of advanced therapies such as antibody-drug conjugates and targeted drugs has significantly improved treatment effectiveness. These therapies combine precision targeting with strong tumor-killing capabilities, enhancing patient outcomes.

Growing Adoption of Combination Therapies

Combination therapies, including immunotherapy with targeted drugs, are creating new growth opportunities. These treatments improve response rates and expand the eligible patient population, driving market expansion.

Market Restraints

Despite strong growth, the market faces challenges due to high treatment costs and reimbursement pressures. Many advanced oncology drugs require strong clinical evidence to justify their cost, leading to delays in reimbursement approvals.

Additionally, limited access to specialized treatment centers and strict regulatory requirements can restrict the adoption of innovative therapies, especially in developing regions.

Market Challenges

A significant challenge in the oncology drugs market is the complex manufacturing process of advanced therapies such as radiopharmaceuticals and antibody-drug conjugates. These treatments require specialized infrastructure, strict handling conditions, and precise logistics.

Supply chain constraints and short shelf-life of certain drugs also hinder widespread accessibility, impacting overall market growth.

Segmentation Analysis

By Drug Class

Targeted drugs dominate the market due to their high efficacy and precision in treating cancer. These include monoclonal antibodies and other advanced therapies. Cytotoxic drugs also continue to grow steadily due to their widespread use.

By Therapy

Targeted therapy leads the segment owing to its ability to specifically attack cancer cells while minimizing damage to healthy tissues. Immunotherapy is expected to grow rapidly due to its effectiveness in enhancing the body's immune response.

By Indication

Lung cancer holds the largest market share due to its high prevalence globally. Breast cancer is also expected to witness significant growth due to increasing awareness and early diagnosis.

By Dosage Form

Injectable drugs dominate the market, as most oncology treatments are administered in clinical settings for better efficacy and monitoring.

By Distribution Channel

Hospital pharmacies lead the market, accounting for the largest share due to the need for specialized administration and monitoring of oncology drugs.

Regional Insights

• North America: Largest market with USD 108.79 billion in 2025, growing to USD 118.41 billion in 2026, driven by innovation and strong healthcare infrastructure.
• Europe: Valued at USD 56.86 billion in 2025 and USD 63.69 billion in 2026, supported by reimbursement policies and advanced treatment adoption.
• Asia Pacific: Rapidly growing region with USD 50.95 billion in 2025 and USD 57.82 billion in 2026, driven by rising patient population in China and India.
• Latin America & Middle East & Africa: Emerging markets with steady growth due to increasing healthcare investment and patient awareness.

Competitive Landscape

The oncology drugs market is moderately fragmented, with major players focusing on innovation, acquisitions, and expanding product pipelines. Leading companies include Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, and Roche. These firms dominate due to their strong portfolios of blockbuster cancer drugs and continuous R&D investments.

Conclusion

The global oncology drugs market is poised for significant expansion, growing from USD 256.46 billion in 2025 to USD 697.59 billion by 2034. This growth is primarily driven by rising cancer prevalence, increasing adoption of targeted and combination therapies, and continuous innovation in drug development.

However, challenges such as high treatment costs, reimbursement barriers, and complex manufacturing processes remain critical concerns. Despite these hurdles, advancements in personalized medicine, early diagnosis, and novel therapeutic approaches are expected to reshape the market landscape.

Segmentation By Drug Class, Therapy, Indication, Dosage Form, Distribution Channel, and Region

By Drug Class * Cytotoxic Drugs

• Alkylating Agents
• Antimetabolites
• Others
• Targeted Drugs
  • Monoclonal Antibodies
  • Others
• Hormonal Drugs
• Others

By Therapy * Chemotherapy

• Targeted Therapy
• Immunotherapy
• Others

By Indication * Lung Cancer

• Stomach Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Others

By Dosage Form * Solid

• Tablets
• Capsules
• Liquid
• Injectable
  • Prefilled Syringes
  • Others

By Distribution Channel * Hospital Pharmacies

• Retail Pharmacies
• Online Pharmacies

By Region * North America (By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)

• U.S. (By Drug Class)
• Canada (By Drug Class)
• Europe (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
  • U.K. (By Drug Class)
  • Germany (By Drug Class)
  • France (By Drug Class)
  • Italy (By Drug Class)
  • Spain (By Drug Class)
  • Scandinavia (By Drug Class)
  • Rest of Europe (By Drug Class)
• Asia Pacific (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
  • Japan (By Drug Class)
  • China (By Drug Class)
  • India (By Drug Class)
  • Australia (By Drug Class)
  • Southeast Asia (By Drug Class)
  • Rest of Asia Pacific (By Drug Class)
• Latin America (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
  • Brazil (By Drug Class)
  • Mexico (By Drug Class)
  • Rest of Latin America (By Drug Class)
• Middle East & Africa (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
  • South Africa (By Drug Class)
  • GCC (By Drug Class)
  • Rest of the Middle East & Africa (By Drug Class)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Cancer, By Region/Country, 2025
• 4.2. Overview of Different Oncology Drugs With Respect to Regulatory Approvals and Clinical Trials
• 4.3. Pricing Analysis, Key Brands / Key Players, 2025
• 4.4. Key Industry Development (Mergers, Acquisitions and Partnerships)

5. Global Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Cytotoxic Drugs
    • 5.1.1.1. Alkylating Agents
    • 5.1.1.2. Antimetabolites
    • 5.1.1.3. Others
  • 5.1.2. Targeted Drugs
    • 5.1.2.1. Monoclonal Antibodies
    • 5.1.2.2. Others
  • 5.1.3. Hormonal Drugs
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Therapy
  • 5.2.1. Chemotherapy
  • 5.2.2. Targeted Therapy
  • 5.2.3. Immunotherapy
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Lung Cancer
  • 5.3.2. Stomach Cancer
  • 5.3.3. Colorectal Cancer
  • 5.3.4. Breast Cancer
  • 5.3.5. Prostate Cancer
  • 5.3.6. Others
• 5.4. Market Analysis, Insights and Forecast - By Dosage Form
  • 5.4.1. Solid
    • 5.4.1.1. Tablets
    • 5.4.1.2. Capsules
  • 5.4.2. Liquid
  • 5.4.3. Injectable
    • 5.4.3.1. Prefilled Syringes
    • 5.4.3.2. Others
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacies
  • 5.5.2. Retail Pharmacies
  • 5.5.3. Online Pharmacies
• 5.6. Market Analysis, Insights and Forecast - By Geography
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Cytotoxic Drugs
    • 6.1.1.1. Alkylating Agents
    • 6.1.1.2. Antimetabolites
    • 6.1.1.3. Others
  • 6.1.2. Targeted Drugs
    • 6.1.2.1. Monoclonal Antibodies
    • 6.1.2.2. Others
  • 6.1.3. Hormonal Drugs
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Therapy
  • 6.2.1. Chemotherapy
  • 6.2.2. Targeted Therapy
  • 6.2.3. Immunotherapy
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Lung Cancer
  • 6.3.2. Stomach Cancer
  • 6.3.3. Colorectal Cancer
  • 6.3.4. Breast Cancer
  • 6.3.5. Prostate Cancer
  • 6.3.6. Others
• 6.4. Market Analysis, Insights and Forecast - By Dosage Form
  • 6.4.1. Solid
    • 6.4.1.1. Tablets
    • 6.4.1.2. Capsules
  • 6.4.2. Liquid
  • 6.4.3. Injectable
    • 6.4.3.1. Prefilled Syringes
    • 6.4.3.2. Others
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacies
  • 6.5.2. Retail Pharmacies
  • 6.5.3. Online Pharmacies
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
    • 6.6.1.1. By Drug Class
  • 6.6.2. Canada
    • 6.6.2.1. By Drug Class

7. Europe Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Cytotoxic Drugs
    • 7.1.1.1. Alkylating Agents
    • 7.1.1.2. Antimetabolites
    • 7.1.1.3. Others
  • 7.1.2. Targeted Drugs
    • 7.1.2.1. Monoclonal Antibodies
    • 7.1.2.2. Others
  • 7.1.3. Hormonal Drugs
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Therapy
  • 7.2.1. Chemotherapy
  • 7.2.2. Targeted Therapy
  • 7.2.3. Immunotherapy
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Lung Cancer
  • 7.3.2. Stomach Cancer
  • 7.3.3. Colorectal Cancer
  • 7.3.4. Breast Cancer
  • 7.3.5. Prostate Cancer
  • 7.3.6. Others
• 7.4. Market Analysis, Insights and Forecast - By Dosage Form
  • 7.4.1. Solid
    • 7.4.1.1. Tablets
    • 7.4.1.2. Capsules
  • 7.4.2. Liquid
  • 7.4.3. Injectable
    • 7.4.3.1. Prefilled Syringes
    • 7.4.3.2. Others
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Retail Pharmacies
  • 7.5.3. Online Pharmacies
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K
    • 7.6.1.1. By Drug Class
  • 7.6.2. Germany
    • 7.6.2.1. By Drug Class
  • 7.6.3. France
    • 7.6.3.1. By Drug Class
  • 7.6.4. Spain
    • 7.6.4.1. By Drug Class
  • 7.6.5. Italy
    • 7.6.5.1. By Drug Class
  • 7.6.6. Scandinavia
    • 7.6.6.1. By Drug Class
  • 7.6.7. Rest of Europe
    • 7.6.7.1. By Drug Class

8. Asia Pacific Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Cytotoxic Drugs
    • 8.1.1.1. Alkylating Agents
    • 8.1.1.2. Antimetabolites
    • 8.1.1.3. Others
  • 8.1.2. Targeted Drugs
    • 8.1.2.1. Monoclonal Antibodies
    • 8.1.2.2. Others
  • 8.1.3. Hormonal Drugs
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Therapy
  • 8.2.1. Chemotherapy
  • 8.2.2. Targeted Therapy
  • 8.2.3. Immunotherapy
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Lung Cancer
  • 8.3.2. Stomach Cancer
  • 8.3.3. Colorectal Cancer
  • 8.3.4. Breast Cancer
  • 8.3.5. Prostate Cancer
  • 8.3.6. Others
• 8.4. Market Analysis, Insights and Forecast - By Dosage Form
  • 8.4.1. Solid
    • 8.4.1.1. Tablets
    • 8.4.1.2. Capsules
  • 8.4.2. Liquid
  • 8.4.3. Injectable
    • 8.4.3.1. Prefilled Syringes
    • 8.4.3.2. Others
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Retail Pharmacies
  • 8.5.3. Online Pharmacies
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
    • 8.6.1.1. By Drug Class
  • 8.6.2. China
    • 8.6.2.1. By Drug Class
  • 8.6.3. India
    • 8.6.3.1. By Drug Class
  • 8.6.4. Australia
    • 8.6.4.1. By Drug Class
  • 8.6.5. Southeast Asia
    • 8.6.5.1. By Drug Class
  • 8.6.6. Rest of Asia Pacific
    • 8.6.6.1. By Drug Class

9. Latin America Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Cytotoxic Drugs
    • 9.1.1.1. Alkylating Agents
    • 9.1.1.2. Antimetabolites
    • 9.1.1.3. Others
  • 9.1.2. Targeted Drugs
    • 9.1.2.1. Monoclonal Antibodies
    • 9.1.2.2. Others
  • 9.1.3. Hormonal Drugs
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Therapy
  • 9.2.1. Chemotherapy
  • 9.2.2. Targeted Therapy
  • 9.2.3. Immunotherapy
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Lung Cancer
  • 9.3.2. Stomach Cancer
  • 9.3.3. Colorectal Cancer
  • 9.3.4. Breast Cancer
  • 9.3.5. Prostate Cancer
  • 9.3.6. Others
• 9.4. Market Analysis, Insights and Forecast - By Dosage Form
  • 9.4.1. Solid
    • 9.4.1.1. Tablets
    • 9.4.1.2. Capsules
  • 9.4.2. Liquid
  • 9.4.3. Injectable
    • 9.4.3.1. Prefilled Syringes
    • 9.4.3.2. Others
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Retail Pharmacies
  • 9.5.3. Online Pharmacies
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
    • 9.6.1.1. By Drug Class
  • 9.6.2. Mexico
    • 9.6.2.1. By Drug Class
  • 9.6.3. Rest of Latin America
    • 9.6.3.1. By Drug Class

10. Middle East & Africa Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Cytotoxic Drugs
    • 10.1.1.1. Alkylating Agents
    • 10.1.1.2. Antimetabolites
    • 10.1.1.3. Others
  • 10.1.2. Targeted Drugs
    • 10.1.2.1. Monoclonal Antibodies
    • 10.1.2.2. Others
  • 10.1.3. Hormonal Drugs
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Therapy
  • 10.2.1. Chemotherapy
  • 10.2.2. Targeted Therapy
  • 10.2.3. Immunotherapy
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Lung Cancer
  • 10.3.2. Stomach Cancer
  • 10.3.3. Colorectal Cancer
  • 10.3.4. Breast Cancer
  • 10.3.5. Prostate Cancer
  • 10.3.6. Others
• 10.4. Market Analysis, Insights and Forecast - By Dosage Form
  • 10.4.1. Solid
    • 10.4.1.1. Tablets
    • 10.4.1.2. Capsules
  • 10.4.2. Liquid
  • 10.4.3. Injectable
    • 10.4.3.1. Prefilled Syringes
    • 10.4.3.2. Others
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Retail Pharmacies
  • 10.5.3. Online Pharmacies
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
    • 10.6.1.1. By Drug Class
  • 10.6.2. South Africa
    • 10.6.2.1. By Drug Class
  • 10.6.3. Rest of the Middle East & Africa
    • 10.6.3.1. By Drug Class

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  • 11.2.1. F. Hoffmann-La Roche Ltd.
  • 11.2.2. AbbVie, Inc.
  • 11.2.3. Novartis AG
  • 11.2.4. Pfizer Inc.
  • 11.2.5. AstraZeneca
  • 11.2.6. GSK plc
  • 11.2.7. Eli Lilly and Company
  • 11.2.8. Sanofi
  • 11.2.9. Bayer AG
  • 11.2.10. Merck & Co., Inc.
  • 11.2.11. Bristol-Myers Squibb Company